Weijing Cai1, Dongmei Lin1, Chunyan Wu1, Xuefei Li1, Chao Zhao1, Limou Zheng1, Shannon Chuai1, Ke Fei1, Caicun Zhou2, Fred R Hirsch1. 1. Weijing Cai, Chunyan Wu, Xuefei Li, Chao Zhao, Ke Fei, and Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai; Dongmei Lin, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Limou Zheng, Xiamen University, Xiamen; Shannon Chuai, Burning Rock Biotech, Guangzhou, People's Republic of China; and Fred R. Hirsch, University of Colorado Cancer Center, Aurora, CO. 2. Weijing Cai, Chunyan Wu, Xuefei Li, Chao Zhao, Ke Fei, and Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai; Dongmei Lin, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing; Limou Zheng, Xiamen University, Xiamen; Shannon Chuai, Burning Rock Biotech, Guangzhou, People's Republic of China; and Fred R. Hirsch, University of Colorado Cancer Center, Aurora, CO. caicunzhoudr@163.com.
Abstract
PURPOSE: Genetic intratumoral heterogeneity has a profound influence on the selection of clinical treatment strategies and on addressing resistance to targeted therapy. The purpose of this study was to explore the potential effect of intratumoral heterogeneity on both genetic and pathologic characteristics of ALK-rearranged lung adenocarcinoma (LADC). METHODS: We tested ALK fusions and EGFR mutations in 629 patients with LADC by using laser-capture microdissection to capture spatially separated tumor cell subpopulations in various adenocarcinoma subtypes and to test for ALK fusions and EGFR mutations in ALK-rearranged, EGFR-mutated, and ALK/EGFR coaltered LADCs to compare the oncogenic driver status between different tumor cell subpopulations in the same primary tumor. RESULTS: Among the 629 patients, 30 (4.8%) had ALK fusions, 364 (57.9%) had EGFR mutations, and two had ALK fusions that coexisted with EGFR mutations. Intratumoral heterogeneity of ALK fusions were identified in nine patients by reverse-transcriptase polymerase chain reaction. In the two patients with an ALK/EGFR coaltered status, genetic intratumoral heterogeneity was observed both between different growth patterns and within the same growth pattern. The relative abundance of ALK and EGFR alterations was different in the same captured area. ALK fusions were positively associated with a micropapillary pattern (P = .002) and were negatively associated with a lepidic pattern (P = .008) in an expanded statistical analysis of 900 individual adenocarcinoma components, although they appeared to be more common in acinar-predominant LADCs in the analysis of 629 patients. CONCLUSION: Intratumoral genetic heterogeneity was demonstrated to coexist with histologic heterogeneity in both single-driver and ALK/EGFR coaltered LADCs. Altered oncogenic drivers in spatially separated subclones of the same tumor may be different.
PURPOSE: Genetic intratumoral heterogeneity has a profound influence on the selection of clinical treatment strategies and on addressing resistance to targeted therapy. The purpose of this study was to explore the potential effect of intratumoral heterogeneity on both genetic and pathologic characteristics of ALK-rearranged lung adenocarcinoma (LADC). METHODS: We tested ALK fusions and EGFR mutations in 629 patients with LADC by using laser-capture microdissection to capture spatially separated tumor cell subpopulations in various adenocarcinoma subtypes and to test for ALK fusions and EGFR mutations in ALK-rearranged, EGFR-mutated, and ALK/EGFR coaltered LADCs to compare the oncogenic driver status between different tumor cell subpopulations in the same primary tumor. RESULTS: Among the 629 patients, 30 (4.8%) had ALK fusions, 364 (57.9%) had EGFR mutations, and two had ALK fusions that coexisted with EGFR mutations. Intratumoral heterogeneity of ALK fusions were identified in nine patients by reverse-transcriptase polymerase chain reaction. In the two patients with an ALK/EGFR coaltered status, genetic intratumoral heterogeneity was observed both between different growth patterns and within the same growth pattern. The relative abundance of ALK and EGFR alterations was different in the same captured area. ALK fusions were positively associated with a micropapillary pattern (P = .002) and were negatively associated with a lepidic pattern (P = .008) in an expanded statistical analysis of 900 individual adenocarcinoma components, although they appeared to be more common in acinar-predominant LADCs in the analysis of 629 patients. CONCLUSION: Intratumoral genetic heterogeneity was demonstrated to coexist with histologic heterogeneity in both single-driver and ALK/EGFR coaltered LADCs. Altered oncogenic drivers in spatially separated subclones of the same tumor may be different.
Authors: Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: Nicholas Navin; Alexander Krasnitz; Linda Rodgers; Kerry Cook; Jennifer Meth; Jude Kendall; Michael Riggs; Yvonne Eberling; Jennifer Troge; Vladimir Grubor; Dan Levy; Pär Lundin; Susanne Månér; Anders Zetterberg; James Hicks; Michael Wigler Journal: Genome Res Date: 2009-11-10 Impact factor: 9.043
Authors: Li Ding; Matthew J Ellis; Shunqiang Li; David E Larson; Ken Chen; John W Wallis; Christopher C Harris; Michael D McLellan; Robert S Fulton; Lucinda L Fulton; Rachel M Abbott; Jeremy Hoog; David J Dooling; Daniel C Koboldt; Heather Schmidt; Joelle Kalicki; Qunyuan Zhang; Lei Chen; Ling Lin; Michael C Wendl; Joshua F McMichael; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Elizabeth Appelbaum; Katherine Deschryver; Sherri Davies; Therese Guintoli; Li Lin; Robert Crowder; Yu Tao; Jacqueline E Snider; Scott M Smith; Adam F Dukes; Gabriel E Sanderson; Craig S Pohl; Kim D Delehaunty; Catrina C Fronick; Kimberley A Pape; Jerry S Reed; Jody S Robinson; Jennifer S Hodges; William Schierding; Nathan D Dees; Dong Shen; Devin P Locke; Madeline E Wiechert; James M Eldred; Josh B Peck; Benjamin J Oberkfell; Justin T Lolofie; Feiyu Du; Amy E Hawkins; Michelle D O'Laughlin; Kelly E Bernard; Mark Cunningham; Glendoria Elliott; Mark D Mason; Dominic M Thompson; Jennifer L Ivanovich; Paul J Goodfellow; Charles M Perou; George M Weinstock; Rebecca Aft; Mark Watson; Timothy J Ley; Richard K Wilson; Elaine R Mardis Journal: Nature Date: 2010-04-15 Impact factor: 49.962
Authors: Scott J Rodig; Mari Mino-Kenudson; Sanja Dacic; Beow Y Yeap; Alice Shaw; Justine A Barletta; Hannah Stubbs; Kenny Law; Neal Lindeman; Eugene Mark; Pasi A Janne; Thomas Lynch; Bruce E Johnson; A John Iafrate; Lucian R Chirieac Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Kristina Anderson; Christoph Lutz; Frederik W van Delft; Caroline M Bateman; Yanping Guo; Susan M Colman; Helena Kempski; Anthony V Moorman; Ian Titley; John Swansbury; Lyndal Kearney; Tariq Enver; Mel Greaves Journal: Nature Date: 2010-12-15 Impact factor: 49.962
Authors: Felipe C Geyer; Britta Weigelt; Rachael Natrajan; Maryou B K Lambros; Dario de Biase; Radost Vatcheva; Kay Savage; Alan Mackay; Alan Ashworth; Jorge S Reis-Filho Journal: J Pathol Date: 2010-04 Impact factor: 7.996
Authors: Xiuyun Jiang; Kevin M Sullivan; Yongwoo David Seo; Florencia G Jalikis; Kimberly S Smythe; Arezou Abbasi; Marissa Vignali; James O Park; Sara K Daniel; Seth M Pollack; Teresa S Kim; Raymond Yeung; Ian Nicholas Crispe; Robert H Pierce; Harlan Robins; Venu G Pillarisetty Journal: Clin Cancer Res Date: 2019-04-02 Impact factor: 12.531
Authors: Sean R Williamson; David J Grignon; Anna Calió; Bradley A Stohr; John N Eble; Liang Cheng Journal: Mod Pathol Date: 2017-10 Impact factor: 7.842